At the Clinical Research Center of Cayetano Heredia University in Lima, the capital of Peru, on the 9th (local time), a medical worker is administering the COVID-19 vaccine produced by China's Sinopharm to the arm of a clinical trial volunteer. [Image source=Yonhap News]
[Asia Economy Reporter Choi Eun-young] Clinical trials of the Chinese COVID-19 vaccine 'Sinopharm' have been halted in Peru. This action was taken after one participant experienced neurological paralysis symptoms as a side effect.
According to AFP and other foreign media on the 11th (local time), the clinical trial was stopped after one participant developed Guillain-Barre syndrome, which rendered them unable to move their arm.
Guillain-Barre syndrome is a condition where inflammation occurs in the peripheral nerves, causing pain and paralysis in the limbs.
Herman Malaga, chief researcher at the National Institute of Health of Peru, announced at a press conference that "one of the trial participants showed neurological symptoms consistent with Guillain-Barre syndrome," and informed about the suspension of the clinical trial.
Initially, Peru had been conducting Sinopharm vaccine clinical trials on approximately 12,000 people. The results of the trial were originally scheduled to be announced this week.
Currently, Sinopharm vaccine clinical trials are being conducted on about 60,000 people in Peru, Argentina, Russia, Saudi Arabia, and other countries. Sinopharm stated, "More than one million people have been vaccinated with our vaccine so far, and there have been no side effects reported," and has announced plans to provide 1 billion doses by next year.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
